Immunodominance and tumor escape.
暂无分享,去创建一个
H. Schreiber | H Schreiber | W. Kast | W M Kast | T H Wu | J Nachman | T. Wu | J. Nachman | T. Wu
[1] J. Klein,et al. Ir-genes in H-2 regulate generation of anti-viral cytotoxic T cells. Mapping to K or D and dominance of unresponsiveness , 1978, The Journal of experimental medicine.
[2] D. Rowley,et al. A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens , 1993, The Journal of experimental medicine.
[3] H. Schreiber,et al. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target , 1993, The Journal of experimental medicine.
[4] D. Longo,et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.
[5] H. Köhler,et al. Clonal Restriction of the Immune Response to Phosphorylcholine , 1974, Nature.
[6] P. Monach,et al. A unique tumor antigen produced by a single amino acid substitution. , 1995, Immunity.
[7] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[8] J. Shabanowitz,et al. The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68 , 1997, The Journal of experimental medicine.
[9] P. Wettstein,et al. Immunodominance in the immune response to “multiple” histocompatibility antigens , 2004, Immunogenetics.
[10] F. Brasseur,et al. A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.
[11] J. Kirkwood,et al. Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading , 2000, Immunological investigations.
[12] C. Waes,et al. Immunodominant deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro , 1996 .
[13] F. Garrido,et al. HLA and cancer: from research to clinical impact. , 1998, Immunology today.
[14] H. Schreiber,et al. Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Mulé,et al. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[17] H. Schreiber,et al. Multiple tumour-specific antigens expressed on a single tumour cell , 1983, Nature.
[18] P. Grufman,et al. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery. , 1998, Journal of immunology.
[19] G. Klein,et al. Evolution of tumours and the impact of molecular oncology , 1985, Nature.
[20] C. Van Waes,et al. Pecking order among tumor‐specific antigens , 1984, European journal of immunology.
[21] S. H. van der Burg,et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.
[22] J. Bennink,et al. Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype , 1978, The Journal of experimental medicine.
[23] H. Schreiber,et al. Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones. , 1983, Journal of immunology.
[24] J. Davie,et al. CLONAL NATURE OF THE IMMUNE RESPONSE TO PHOSPHORYLCHOLINE , 1974, The Journal of experimental medicine.
[25] H. Schreiber,et al. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells , 1992, The Journal of experimental medicine.
[26] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[27] W. Storkus,et al. B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .
[28] J. Bluestone,et al. Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.
[29] P. Coulie,et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[30] Melief Cj,et al. Prospects for T Cell Immunotherapy of Tumours by Vaccination with Immunodominant and Subdominant Peptides , 1994 .
[31] M. Kripke,et al. Stepwise immunologic selection of antigenic variants during tumor growth. , 1986, Journal of immunology.
[32] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[33] C. Van Waes,et al. Multiple cancers. Tumor burden permits the outgrowth of other cancers , 1985, The Journal of experimental medicine.